Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAR-200 in muscle-invasive bladder cancer
NCT03404791Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2017
- Primary completion
- Dec 2019
- Modality
- Small Molecules, Device-based Delivery
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of gemcitabine-releasing intravesical system in muscle-invasive bladder cancer (MIBC), sponsored by Janssen Pharmaceutical. Primary endpoint: Number of Participants with Adverse Events as a Measure of Safety and Tolerability. Started Nov 2017; status: completed.
02
Drugs
gemcitabine-releasing intravesical system
03
Conditions
muscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on NCT03404791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03404791.